Assignee
XIGEN INFLAMMATION LTD
CY·8 granted patents·13 pending applications·16 citations·filing 2012–2022
Top patents by PatentIndex Score
21 records- 0190US9624267B2JNK inhibitor moleculesXIGEN INFLAMMATION LTD·Filed 2015·Granted Apr 18, 2017·5 cites·11 claims
- 0286US9610330B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2015·Granted Apr 4, 2017·5 cites·14 claims
- 0385US9290538B2Cell-permeable peptide inhibitors of the JNK signal transduction pathwayXIGEN INFLAMMATION LTD·Filed 2013·Granted Mar 22, 2016·5 cites·18 claims
- 0476US10596223B2JNK inhibitor molecules for treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2016·Granted Mar 24, 2020·1 cites·5 claims
- 0569US2022280591A1Use For JNK Inhibitor Molecules For Treatment Of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2022·Application pending·0 cites
- 0666US2020062805A1Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction PathwayXIGEN INFLAMMATION LTD·Filed 2019·Application pending·0 cites
- 0760US2017320917A1Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction PathwayXIGEN INFLAMMATION LTD·Filed 2017·Application pending·0 cites
- 0859US2015133393A1Novel JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2012·Application pending·0 cites
- 0959US2020206301A1JNK Inhibitor Molecules For Treatment Of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2020·Application pending·0 cites
- 1056US11779628B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2015·Granted Oct 10, 2023·0 cites·1 claims
- 1156US2016264630A1Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction PathwayXIGEN INFLAMMATION LTD·Filed 2016·Application pending·0 cites
- 1255US10967038B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseasesXIGEN INFLAMMATION LTD·Filed 2018·Granted Apr 6, 2021·0 cites·2 claims
- 1354US2016115200A1New Use for JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2014·Application pending·0 cites
- 1452US2019337988A1Novel transporter constructs and transporter cargo conjugate moleculesXIGEN INFLAMMATION LTD·Filed 2018·Application pending·0 cites
- 1549US10624948B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2014·Granted Apr 21, 2020·0 cites·8 claims
- 1645US11331364B2Use for JNK inhibitor molecules for treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2019·Granted May 17, 2022·0 cites·17 claims
- 1745US2014309400A1Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye SyndromeXIGEN INFLAMMATION LTD·Filed 2012·Application pending·0 cites
- 1844US2017128516A1Use for JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 1943US2016089413A1Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 2038US2017137481A1Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 2136US2018170983A1New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive ImpairmentXIGEN INFLAMMATION LTD·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →